Torrent Pharma Clears USFDA Inspection with Zero Observations

delivered a key regulatory milestone as the USFDA inspection of its Dahej (Gujarat) manufacturing facility, conducted between January 19–23, 2026, concluded with zero observations, indicating no deficiencies in its manufacturing processes or quality systems. This “clean chit” reflects adherence to stringent global compliance standards and strengthens the company’s credibility in regulated markets like the U.S. Notably, zero observations are rare in such inspections and signal robust operational controls, which can support smoother approvals and future product filings. The company formally disclosed this development to stock exchanges under SEBI’s Regulation 30, reinforcing transparency.